17-(benzimidazol-1-yl)-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-3-ol

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 17-(benzimidazol-1-yl)-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-3-ol
• 化学式: C₂₆H₃₂N₂O
• 分子量: 388.5
• InChiKey: PAFKTGFSEFKSQG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  29
• 可旋转键数：
  1
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  38
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] PROCESS FOR THE PREPARATION OF 3ß-HYDROXY-17-(1H-BENZIMIDAZOL-1-YL)ANDROSTA-5,16-DIENE<br/>[FR] PROCÉDÉ DE PRÉPARATION DE 3B-HYDROXY-17-(1H-BENZIMIDAZOL-1-YL) ANDROSTA -5,16-DIÈNE
  申请人：IND CHIMICA SRL

  公开号：WO2018029223A1

  公开（公告）日：2018-02-15

  A process for the synthesis of β-hydroxy 3-17-(1H-benzimidazol-1-yl)androsta-5,16-diene is described, a compound also known as Galeterone and used in the treatment of prostate cancer, having the formula (6).

  本文描述了一种合成β-羟基3-17-(1H-苯并咪唑-1-基)雄甾-5,16-二烯的过程，该化合物也称为Galeterone，用于治疗前列腺癌，其化学式为(6)。
• PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF
  申请人：Kangpu Biopharmaceuticals, Ltd.

  公开号：EP3357513A1

  公开（公告）日：2018-08-08

  Disclosed are a pharmaceutical composition and an application thereof. The pharmaceutical composition includes one or more of a benzoheterocyclic compound as shown in formula (I), a pharmaceutically acceptable salt thereof, a solvate thereof, a crystalline form thereof, a co-crystal thereof, a stereoisomer thereof, an isotope compound thereof, a metabolite thereof and a prodrug thereof, and an androgen receptor pathway modulator. The pharmaceutical composition better inhibits prostate cancer cell growth.

  公开了一种药物组合物及其应用。该药物组合物包括一种或多种如式（I）所示的苯并杂环化合物、其药学上可接受的盐、其溶液、其晶体、其共晶体、其立体异构体、其同位素化合物、其代谢物和其原药，以及雄激素受体通路调节剂。该药物组合物能更好地抑制前列腺癌细胞的生长。
• COMPOSITION, APPLICATION THEREOF AND TREATMENT METHOD
  申请人：Kangpu Biopharmaceuticals, Ltd.

  公开号：EP3527210A1

  公开（公告）日：2019-08-21

  Provided are a combination, an application thereof and a treatment method. The combination comprises one or more of a benzoheterocyclic compound of formula (I), a pharmaceutically acceptable salt, a solvate, a crystalline form, a cocrystal, a stereoisomer, an isotope compound, a metabolite and a prodrug thereof, and an androgen receptor pathway modulator and/or a hormone drug. The combination and treatment method may effectively inhibit the growth of prostate cancer cells.

  本文提供了一种组合物、其应用和治疗方法。该组合物包括一种或多种式（I）的苯并杂环化合物、药学上可接受的盐、溶液、结晶体、共晶体、立体异构体、同位素化合物、其代谢物和原药，以及雄激素受体通路调节剂和/或激素药物。这种组合和治疗方法可有效抑制前列腺癌细胞的生长。
• COMBINATION TREATING PROSTATE CANCER, PHARMACEUTICAL COMPOSITION AND TREATMENT METHOD
  申请人：Kangpu Biopharmaceuticals, Ltd.

  公开号：EP3581182B1

  公开（公告）日：2021-09-29
• MODULATION OF ANDROGEN RECEPTOR EXPRESSION
  申请人：ISIS Pharmaceuticals Inc.

  公开号：US20160068846A1

  公开（公告）日：2016-03-10

  Certain embodiments are directed to compounds and compositions targeted to human androgen receptor (AR) for inhibiting androgen receptor levels in a cell, which can be useful for methods of treating cancer and inhibiting cancer cell growth or proliferation.